New Flexible Polymeric Heart Valve Prostheses for the Mitral and Aortic Positions

Authors

  • Sabine H. Daebritz
  • Bernd Fausten
  • Benita Hermanns
  • Andreas Franke
  • Joerg Schroeder
  • Jan Groetzner
  • Ruediger Autschbach
  • Bruno J. Messmer
  • Jörg S. Sachweh

DOI:

https://doi.org/10.1532/HSF98.20041083

Abstract

Objective: Current prosthetic heart valves necessitate permanent anticoagulation or have limited durability and impaired hemodynamic performance compared with natural valves. We report in vivo and in vitro results with new polymeric valve prostheses that have a special design for the mitral and aortic positions. The aims are improved durability and elimination of the need for permanent anticoagulation.

Methods: The mitral and aortic prostheses (Adiam Life Science, Erkelenz, Germany) are made entirely of polycarbonate urethane (PCU). The bileaflet asymmetric mitral valve mimics natural, nonaxial inflow, which creates a left ventricular vortex, saving energy for systolic ejection of blood. The trileaflet aortic prosthesis has diminished pressure loss and reduced stress and strain peaks at the commissures. The valves were subjected to long-term in vitro testing and in vivo testing in a growing calf model (20 weeks; 7 mitral and 7 aortic valves) with comparison with 2 commercial bioprostheses (7 mitral, 2 aortic). Two-dimensional echocardiography was performed after implantation and prior to sacrifice with autopsy and valve examination.

Results: In vitro durability of the PCU valves was proved up to 20 years. In vivo durability and hemodynamics were superior to those of all bioprostheses. Survival of PCU valves versus bioprostheses was 7 versus 2 mitral valves and 5 versus 0 aortic valves, respectively. Two animals with PCU aortic valves died of pannus overgrowth that caused severe left ventricular outflow tract obstruction without changes in the valves. Degeneration and calcification were mild (mitral) and moderate (aortic) in PCU valves but were severe in biological valves. There was no increased thrombogenicity of the PCU valves compared with bioprostheses. Conclusion: The new flexible polymeric aortic and mitral valve prostheses were superior to current bioprostheses in animal testing.

References

Braunwald NS, Morrow AG. 1965. A late evaluation of flexible Teflon< prostheses utilized for total aortic valve replacement. J Throac Cardiovasc Surg 49:485-96.nChetta GE, Lloyd JR. 1980. The design, fabrication and evaluation of a trileaflet prosthetic heart valve. J Biomech Eng 102:34-41.nDaebritz SH, Bernd Fausten B, Hermanns B, et al. 2004. Introduction of a flexible polymeric heart valve prosthesis with special design for aortic position. Eur J Cardiothorac Surg 25:946-52.nDaebritz SH, Sachweh JS, Hermanns B, et al. 2003. Introduction of a flexible polymeric heart valve prosthesis with special design for mitral position. Circulation 108(suppl 1):II134-9.nDellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H. 2002. Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 124:146-54.nEdmunds LH Jr. 1996. Is prosthetic valve thrombogenicity related to design or material? Texas Heart Inst J 23:24-7.nEichinger WB, Botzenhardt F, Gunzinger R, et al. 2002. European experience with the Mosaic bioprosthesis. J Thorac Cardiovasc Surg 124:333-9.nFood and Drug Administration. 1994. Replacement heart valve: guidance for data to be submitted to the Food and Drug Administration in support of applications for premarket approval. Rockville, Md: Food and Drug Administration.nHerold M, Lo HB, Reul H, et al. 1987. The Helmholtz Institute tri-leaflet polyurethane heart valve prosthesis: design, manufacture, and first in vitro and in vivo results. In: Planck H, Syre I, Dauner M, Egbers G, eds. Polyurethanes in Biomedical Engineering II. Amsterdam: Elsevier.nHilbert SL, Ferrans VJ, Tomita Y, Eidbo EE, Jones M. 1987. Evaluation of explanted polyurethane trileaflet cardiac valve prostheses. J Thorac Cardiovasc Surg 94:419-29.nHufnagel CA. 1977. Reflections on the development of valvular prostheses. Med Instrum 11:74-6.nHyde JA, Chinn JA, Phillips RE Jr. 1999. Polymer heart valves. J Heart Valve Dis 8:331-9.nImamura E, Kaye MP. 1977. Function of expanded-polytetrafluoroethylene laminated trileaflet valves in animals. Mayo Clin Proc 52:770-5.nJansen J, Willeke S, Reiners B, et al. 1991. Advances in design principle and fluid dynamics of a flexible polymeric heart valve. ASAIO Trans 37:451-3.nLo HB, Herold M, Reul H, et al. 1988. A tricuspid polyurethane heart valve as an alternative to mechanical prostheses or bioprostheses. ASAIO Trans 34:839-44.nLupinetti FM, Duncan BW, Scifres AM, et al. 1999. Intermediate-term results in pediatric aortic valve replacement. Ann Thorac Surg 68:521-6.nMarchand MA, Aupart MR, Norton R, et al. 2001. Fifteen-year experience with the mitral Carpentier-Edwards Perimount pericardial bioprosthesis. Ann Thorac Surg 71(suppl):236-9.nNistal F, Garcia-Martinez V, Arbe E, et al. 1990. In vivo experimental assessment of polytetrafluoroethylene trileaflet heart valve prosthesis. J Thorac Cardiovasc Surg 99:1074-81.nReul H, Talukder N. 1979. Heart valve mechanics. In: Hwang NHC, Gross DR, Patel DJ, eds. Quantitative cardiovascular studies: clinical and research applications of engineering principles. Baltimore: University Park Press; 12:527-64.nRoe BB, Kelly PB, Myers JL, Moore DW. 1966. Tricuspid leaflet aortic valve prosthesis. Circulation 33:124-7.nRoe BB, Moore D. 1958. Design and fabrication of prosthetic valves. Exp Med Surg 16:167-77.nSchoen FJ, Harasaki H, Kim KM, Anderson C, Levy RJ. 1988. Biomaterial-associated calcification: pathology, mechanisms, and strategy of prevention. J Biomed Mater Res 22:11-36.nStarr A, Edwards ML. 1961. Mitral valve replacement: clinical experience with a ball valve prosthesis. Ann Surg 154:726-40.nWheatley DJ, Raco L, Bernacca GM, Sim I, Belcher PR, Boyd. 2000. Polyurethane: material for the next generation of heart valve prostheses? Eur J Cardiothorac Surg 17:440-8.nWisman CB, Pierce WS, Donachy JH, Pae WE, Myers JL, Prophet GA. 1982. A polyurethane trileaflet cardiac valve prosthesis: in vitro and in vivo studies. Trans Am Soc Artif Intern Organs 28:164-8.nZdrahala RJ, Zdrahala IJ. 1999. Biomedical applications of polyurethanes: a review of past promises, present realities and a vibrant future. J Biomater Appl 14:67-90.n

Published

2005-01-04

How to Cite

Daebritz, S. H., Fausten, B., Hermanns, B., Franke, A., Schroeder, J., Groetzner, J., Autschbach, R., Messmer, B. J., & Sachweh, J. S. (2005). New Flexible Polymeric Heart Valve Prostheses for the Mitral and Aortic Positions. The Heart Surgery Forum, 7(5), E525-E532. https://doi.org/10.1532/HSF98.20041083

Issue

Section

Article